儿童与妊娠期血铅升高筛查:美国预防服务工作组更新证据报告与系统综述
本系统综述纳入24项研究(N=11433),评估初级保健中对5岁及以下儿童和孕妇进行血铅升高筛查、检测与治疗的效果。儿童中,1991年CDC筛查问卷阳性回答超过1项识别静脉血铅大于10 μg/dL的合并灵敏度为48%、特异度为58%;毛细管血铅检测灵敏度87%至91%、特异度大于90%。螯合剂在儿童中无持续降低血铅的显著效应但存在危害。孕妇证据有限。
要点
- 1991年CDC筛查问卷识别儿童静脉血铅大于10 μg/dL的合并灵敏度48%、特异度58%。
- 毛细管血铅检测较静脉测量灵敏度87%至91%、特异度大于90%。
- DMSA螯合治疗无持续血铅降低效应,与线性生长小幅落后和认知结局较差相关。
核心结论
- 筛查问卷不能准确识别血铅升高的儿童。
- 螯合剂在儿童中与血铅水平持续效应无显著关联,但与危害相关。
- 孕妇筛查问卷准确性及治疗获益与危害的证据过于有限。
研究设计与样本
- 美国预防服务工作组委托的系统综述,检索Cochrane CENTRAL、Cochrane系统综述数据库(至2018年6月)和Ovid MEDLINE(1946年至2018年6月),监测至2018年12月5日。
- 纳入英文试验和观察性研究,评估无症状儿童和孕妇血铅升高的筛查与治疗。
- 由2名评价者独立使用预设标准进行批判性评价和数据提取。
- 共纳入24项研究(N=11433)。
主要发现
- 无研究评估儿童筛查与不筛查的获益或危害。
- 1991年CDC 5项筛查问卷阳性回答超过1项识别静脉血铅大于10 μg/dL的合并灵敏度48%(95% CI,31.4%至65.6%)、特异度58%(95% CI,39.9%至74.0%)(5项研究[n=2265])。
- 改编版CDC问卷未显示准确性改善。
- 毛细管血铅检测较静脉测量灵敏度87%至91%、特异度大于90%(4项研究[n=1431])。
- 咨询与营养干预或住宅铅危害控制技术未降低无症状儿童血铅浓度,但研究少且存在方法学局限(7项研究[n=1419])。
关键数值与推荐
- 1991年CDC筛查问卷阳性回答超过1项识别静脉血铅大于10 μg/dL的合并灵敏度48%(95% CI,31.4%至65.6%)、特异度58%(95% CI,39.9%至74.0%)。
- 毛细管血铅检测较静脉测量灵敏度87%至91%、特异度大于90%。
- DMSA螯合治疗儿童7年随访身高差1.17 cm(95% CI,0.41至1.93),注意与执行功能子评分未调整差异-1.8(95% CI,-4.5至1.0),调整P=.045。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无研究评估儿童筛查与不筛查的获益或危害。
- 咨询与营养干预或住宅铅危害控制技术的研究少且存在方法学局限。
- 孕妇筛查问卷准确性或治疗获益与危害的证据过于有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Elevated blood lead level is associated with serious, often irreversible, health consequences. OBJECTIVE: To synthesize evidence on the effects of screening, testing, and treatment for elevated blood lead level in pregnant women and children aged 5 years and younger in the primary care setting to inform the US Preventive Services Task Force. DATA SOURCES: Cochrane CENTRAL and Cochrane Database of Systematic Reviews (through June 2018) and Ovid MEDLINE (1946 to June 2018); surveillance through December 5, 2018. STUDY SELECTION: English-language trials and observational studies of screening for and treating elevated lead levels in asymptomatic children and pregnant women. DATA EXTRACTION AND SYNTHESIS: Independent critical appraisal and data abstraction by 2 reviewers using predefined criteria. MAIN OUTCOMES AND MEASURES: Elevated blood lead level, morbidity, mortality, clinical prediction tools, test accuracy, adverse events. RESULTS: A total of 24 studies (N = 11 433) were included in this review. No studies evaluated the benefits or harms of screening vs no screening in children. More than 1 positive answer on the 5-item 1991 Centers for Disease Control and Prevention (CDC) screening questionnaire was associated with a pooled sensitivity of 48% (95% CI, 31.4% to 65.6%) and specificity of 58% (95% CI, 39.9% to 74.0%) for identifying children with a venous blood lead level greater than 10 μg/dL (5 studies [n = 2265]). Adapted versions of the CDC questionnaire did not demonstrate improved accuracy. Capillary blood lead testing demonstrated sensitivity of 87% to 91% and specificity greater than 90%, compared with venous measurement (4 studies [n = 1431]). Counseling and nutritional interventions or residential lead hazard control techniques did not reduce blood lead concentrations in asymptomatic children, but studies were few and had methodological limitations (7 studies [n = 1419]). One trial (n = 780) of dimercaptosuccinic acid (DMSA) chelation therapy found reduced blood lead levels in children at 1 week to 1 year but not at 4.5 to 6 years, while another trial (n = 39) found no effect at 1 and 6 months. Seven-year follow-up assessments showed no effect on neuropsychological development, a small deficit in linear growth (height difference, 1.17 cm [95% CI, 0.41 to 1.93]), and poorer cognitive outcomes reported as the Attention and Executive Functions subscore of the Developmental Neuropsychological Assessment (unadjusted difference, -1.8 [95% CI, -4.5 to 1.0]; adjusted P = .045) in children treated with DMSA chelation. Evidence was too limited to determine the accuracy of screening questionnaires or benefits and harms of treatment in pregnant women. CONCLUSIONS AND RELEVANCE: Screening questionnaires were not accurate for identifying children with elevated blood lead levels. Chelating agents in children were not significantly associated with sustained effects on blood level levels but were associated with harms.
引用
- Cantor AG, Hendrickson R, Blazina I, et al. Screening for Elevated Blood Lead Levels in Childhood and Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 30990555. doi:10.1001/jama.2019.1004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。